Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2016-2018 Final Report
DOI:
https://doi.org/10.33321/cdi.2022.46.28Keywords:
vaccine preventable disease, surveillance, AustraliaAbstract
This summary report on vaccine preventable diseases (VPDs) in Australia brings together the three most important national sources of routinely-collected data on VPDs (notifications, hospitalisations and deaths) for all age groups for the three-year period 1 January 2016 to 31 December 2018. Information about each VPD is provided in 16 chapters using a standard structure.
Changes in the National Immunisation Program (NIP) between 2016 and 2018 are listed below:
1. Addition of a booster dose of diphtheria-tetanus-acellular pertussis vaccine (DTPa) at 18 months (March 2016).
2. Replacement of trivalent influenza vaccine with quadrivalent influenza vaccines (from 2016), and availability of two enhanced trivalent vaccines (high-dose and adjuvanted vaccines), for people aged 65 years and older (in 2018).
3. Addition of a single dose of live attenuated herpes zoster vaccine for people aged 70 years from November 2016, with a five-year catch-up program for 71- to 79-year olds.
4. Replacement of the quadrivalent human papillomavirus (HPV) vaccine (4vHPV) for adolescents with a nonavalent HPV vaccine (9vHPV) in January 2018.
5. Replacement of the 12-month dose of combination Haemophilus influenzae type b–meningococcal serogroup C vaccine (Hib-MenC) with a single dose of quadrivalent meningococcal conjugate (MenACWY) vaccine, with monovalent Hib vaccine given at 18 months of age (July 2018).
6. Change in the timing of routine infant doses of 13-valent pneumococcal conjugate vaccine (PCV13) from 2, 4, and 6 months (3+0 schedule) to 2, 4, and 12 months (2+1 schedule), commencing July 2018. The schedule remained as 2, 4, 6, and 12 months (3+1) for Aboriginal and Torres Strait Islander children in the Northern Territory, South Australia, Queensland and Western Australia, and for children with specified underlying medical conditions.
7. Addition of a dose of diphtheria-tetanus-acellular pertussis vaccine (dTpa) for all women in the third trimester of pregnancy, from July 2018 (replacing funding by states and territories).
Notifications, hospitalisations and deaths in this three-year reporting period and the previous four-year reporting period (2016–2018 and 2012–2015) are summarised in Table 1. Influenza, pertussis and rotavirus were the most commonly notified conditions whereas the most common causes of hospitalisation were influenza, zoster, rotavirus and pneumococcal disease. There were no notifications or hospitalisations due to polio and a continuing low incidence of diphtheria, rubella and tetanus.
Downloads
References
Wattiaux AL, Yin JK, Beard F, Wesselingh S, Cowie B, Ward J et al. Hepatitis B immunization for Indigenous adults, Australia. Bull World Health Organ. 2016;94(11):826–34A.
Chiew M, Dey A, Martin N, Wang H, Davis S, McIntyre PB. Australian vaccine preventable disease epidemiological review series: measles 2000–2011. Commun Dis Intell Q Rep. 2015;39(1):E1–9.
Measles & Rubella Initiative. Four Western Pacific Countries and areas are the first in their Region to be measles-free. [Internet.] Washington DC: American Red Cross, Measles & Rubella Initiative; 20 March 2014. [Accessed on 23 May 2021.] Available from: https://measlesrubellainitiative.org/measles-news/four-western-pacific-countries-areas-first-region-measles-free/.
Gidding HF, Martin NV, Stambos V, Tran T, Dey A, Dowse GK. Verification of measles elimination in Australia: application of World Health Organization regional guidelines. J Epidemiol Glob Health. 2016;6(3):197–209.
Bangor-Jones RD, Dowse GK, Giele CM, van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191(7):398–401.
Bag SK, Dey A, Wang H, Beard FH. Australian vaccine preventable disease epidemiological review series: Mumps 2008–2012. Commun Dis Intell Q Rep. 2015;39(1):E10–8.
Westphal D, Davies J, Huppatz C, Eastwood A, Gilles M, Lyttle H et al. The epidemiology of a large mumps outbreak in Western Australia. Canberra: Public Health Association of Australia; 12 July 2017. [Accessed on 23 May 2021.] Available from: https://www.phaa.net.au/documents/item/2228.
Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the “forgotten” age group in the 1998 Australian Measles Control Campaign. Med J Aust. 2008;189(8):434–7.
Senanayake SN. Mumps: a resurgent disease with protean manifestations. Med J Aust. 2008;189(8):456–9.
World Health Organization (WHO). Singapore wipes out measles; Australia, Brunei Darussalam and Macao SAR (China) eliminate rubella. [Internet.] Geneva: WHO; 31 October 2018. [Accessed on 23 May 2021.] Available from: https://www.who.int/westernpacific/news/detail/31-10-2018-singapore-wipes-out-measles-australia-brunei-darussalam-and-macao-sar-(china)-eliminate-rubella.
Gidding H, Dey A, Macartney K. Australia has eliminated rubella – but that doesn’t mean it can’t come back. [Internet.] Melbourne: The Conversation Media Group Ltd; 2 November 2018. [Accessed on 23 May 2021.] Available from: https://theconversation.com/australia-has-eliminated-rubella-but-that-doesnt-mean-it-cant-come-back-106056.
Dey A, Wang H, Beard F, Macartney K, McIntyre P. Summary of national surveillance data on vaccine preventable diseases in Australia, 2012-2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.58.
Maguire JE, Beard F, Méder K, Dey A, Macartney K, McIntyre P. Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000-2017. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.11.
Marshall KS, Quinn H, Pillsbury AJ, Maguire JE, Lucas RM, Dey A et al. Australian vaccine preventable disease epidemiological review series: Pertussis, 2013–2018. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.3.
Public Health Committee, National Health and Medical Research Council (NHMRC). Surveillance case definitions: endorsed at the 115th Session of NHMRC, Adelaide, June 1993. Canberra: NHMRC; 1994.
Australian Government Department of Health. Australian national notifiable diseases and case definitions. [Internet.] Canberra: Australian Government Department of Health, Communicable Diseases Network Australia (CDNA); 2021. [Accessed on 23 May 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedefinitions.htm.
CDNA Surveillance Case Definitions Working Group. Editorial: Notifiable diseases, Australia, 2004. Commun Dis Intell Q Rep. 2004;28(1):1–5.
Ioannides S, Beard F, Larter N, Clark K, Wang H, Hendry A et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2011–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.36.
Australian Institute of Health and Welfare (AIHW). Indigenous identification in hospital separations data: quality report. (Cat. no. IHW 90.) Canberra: Australian Government, AIHW; 1 May 2013. [Accessed on 23 May 2021.] Available from: https://www.aihw.gov.au/reports/indigenous-australians/indigenous-identification-in-hospital-separations/contents/table-of-contents.
Australian Government Department of Health. Australian national notifiable diseases and case definitions. [Internet.] Canberra: Australian Government Department of Health; 2021. [Accessed on 23 May 2021.] Available from: http://www.health.gov.au/casedefinitions.
National Centre for Immunisation Research and Surveillance (NCIRS). History of immunisation in Australia. [Internet.] Sydney: NCIRS; 2021. [Accessed on 23 May 2021.] Available from: https://www.ncirs.org.au/health-professionals/history-immunisation-australia.
Commonwealth of Australia. Project agreement for vaccine preventable diseases surveillance program. Canberra: Australian Government; 2017. Available from: https://www.federalfinancialrelations.gov.au/content/npa/health/project-agreement/Vaccines_Preventable_Diseases_Surveillance_Program.pdf.
AIHW. Admitted patient care: 2015-16. Australian Hospital Statistics. (Health Services Series, Number 75.) Canberra: Australian Government; AIHW; 2017. [Accessed on 23 May 2021.] Available from: https://www.aihw.gov.au/getmedia/3e1d7d7e-26d9-44fb-8549-aa30ccff100a/20742.pdf.
AIHW. Web update: Potentially preventable hospitalisations in 2015–16. Technical note. Canberra: Australian Government, AIHW; 2017. [Accessed on 23 May 2021.] Available from: https://www.aihw.gov.au/getmedia/14ba43a3-9ae9-4b19-beb9-e9c714e2fb3f/aihw-mhc-hpf-37-technical-note.pdf.
Australian Bureau of Statistics (ABS). Causes of Death, Australia methodology. Reference period 2018. [Internet.] Canberra: ABS; 25 September 2019. [Accessed on 14 February 2021.] Available from: https://www.abs.gov.au/methodologies/causes-death-australia-methodology/2018.
Sheel M, Macartney K. Have you had your diphtheria vaccines? Here’s why it matters. [Internet.] Melbourne: The Conversation Media Group Ltd; 8 August 2018. Available from: https://theconversation.com/have-you-had-your-diphtheria-vaccines-heres-why-it-matters-98174.
WHO. Surveillance standards for vaccine-preventable diseases: diphtheria. Geneva: World Health Organization; 5 September 2018. [Accessed on 14 February 2021.] Available from: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_04_Diphtheria_R2.pdf.
Hatanaka A, Tsunoda A, Okamoto M, Ooe K, Nakamura A, Miyakoshi M et al. Corynebacterium ulcerans diphtheria in Japan. Emerg Infect Dis. 2003;9(6):752–3.
DeWinter LM, Bernard KA, Romney MG. Human clinical isolates of Corynebacterium diphtheriae and Corynebacterium ulcerans collected in Canada from 1999 to 2003 but not fitting reporting criteria for cases of diphtheria. J Clin Microbiol. 2005;43(7):3447–9.
Tiwari TS, Golaz A, Yu DT, Ehresmann KR, Jones TF, Hill HE et al. Investigations of 2 cases of diphtheria-like illness due to toxigenic Corynebacterium ulcerans. Clin Infect Dis. 2008;46(3):395–401.
Elden S, Coole L, Efstratiou A, Doshi N. Laboratory-confirmed case of toxigenic Corynebacterium ulcerans. Euro Surveill. 2007;12(3). doi: https://doi.org/10.2807/esw.12.13.03166-en.
Moore LSP, Leslie A, Meltzer M, Sandison A, Efstratiou A, Sriskandan S. Corynebacterium ulcerans cutaneous diphtheria. Lancet Infect Dis. 2015;15(9):1100–7.
WHO. Diphtheria vaccine: WHO position paper, August 2017 – Recommendations. Vaccine. 2018;36(2):199–201.
Diphtheria. In Heymann DL, ed. Control of Communicable Diseases Manual (19th edition). Washington, DC: American Public Health Association (APHA), 2008;195-200.
Tiwari TSP, Wharton M. 19 – Diphtheria toxoid. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;261–75.e7. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000195.
Australian Government Department of Health. Diphtheria case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 2017. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_dipth.htm.
Lu X, Quinn HE, Menzies RI, Hueston L, Gilbert L, McIntyre PB. Diphtheria immunity in Australia: should we be concerned? Infect Disord Drug Targets. 2020;20(3):323–9.
Paveenkittiporn W, Sripakdee S, Koobkratok O, Sangkitporn S, Kerdsin A. Molecular epidemiology and antimicrobial susceptibility of outbreak-associated Corynebacterium diphtheriae in Thailand, 2012. Infect Genet Evol. 2019;75. doi: https://doi.org/10.1016/j.meegid.2019.104007.
Rahman MR, Islam K. Massive diphtheria outbreak among Rohingya refugees: lessons learnt. J Travel Med. 2019;26(1). doi: https://doi.org/10.1093/jtm/tay122.
Sangal L, Joshi S, Anandan S, Balaji V, Johnson J, Satapathy A. Resurgence of diphtheria in North Kerala, India, 2016: laboratory supported case-based surveillance outcomes. Front Public Health. 2017;5:218.
Harapan H, Anwar S, Dimiati H, Hayati Z, Mudatsir M. Diphtheria outbreak in Indonesia, 2017: An outbreak of an ancient and vaccine-preventable disease in the third millennium. Clin Epidemiol Glob Health. 2019;7(2):261–2.
McIntyre P. Vaccines against invasive Haemophilus influenzae type b disease. J Paediatr Child Health. 1994;30(1):14–8.
Wang H, Deeks S, Glasswell A, McIntyre P. Trends in invasive Haemophilus influenzae type b disease in Australia, 1995–2005. Commun Dis Intell Q Rep. 2008;32(3):316–25.
Hanna JN, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. Med J Aust. 1991;155(3):160–4.
McIntyre PB, O’Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380(9854):1703–11.
McIntyre PB, Leeder SR, Irwig LM. Invasive Haemophilus influenzae type b disease in Sydney children 1985–1987: a population-based study. Med J Aust. 1991;154(12):832–7.
Cleland G, Leung C, Wan Sai Cheong J, Francis J, Heney C, Nourse C. Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: young Indigenous children remain at highest risk. J Paediatr Child Health. 2018;54(1):36–41.
Menzies RI, Bremner KM, Wang H, Beard FH, McIntyre PB. Long-term trends in invasive Haemophilus influenzae type B disease among indigenous Australian children following use of PRP-OMP and PRP-T vaccines. Pediatr Infect Dis J. 2015;34(6):621–6.
Heath PT, Booy R, Azzopardi HJ, Slack MP, Fogarty J, Moloney AC et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J. 2001;20(3):300–5.
Ladhani S, Heath PT, Slack MPE, McIntyre PB, Diez-Domingo J, Campos J et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect. 2010;16(7):948–54.
Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust. 2004;181(9):482–5.
Australian Government Department of Health. Haemophilus influenzae type B (Hib) infection (invasive) case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 2014. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hib.htm.
NSW Health. Communicable Diseases Weekly Report: Week 21, 21 May to 27 May 2017. Sydney: Government of New South Wales Department of Health; 2017. Available from: https://www.health.nsw.gov.au/Infectious/Reports/Publications/cdwr/2017/CDWR-Week21-2017.pdf.
Australian Government Department of Health. The Australian Immunisation Handbook. [Website.] Canberra: Australian Government Department of Health; 2021. [Accessed on 6 February 2021.] Available from: https://immunisationhandbook.health.gov.au.
[No authors listed.] WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec. 2012;87(28/29):261–76.
Averhoff FM, Khudyakov Y, Nelson NP. 24 – Hepatitis A vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;319–41.e15. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000249.
Koff RS. Hepatitis A. Lancet. 1998;351(9116):1643–9.
Abutaleb A, Kottilil S. Hepatitis A: epidemiology, natural history, unusual clinical manifestations, and prevention. Gastroenterol Clin North Am. 2020;49(2):191–9.
Hanna JN, Warnock TH, Shepherd RW, Selvey LA. Fulminant hepatitis A in indigenous children in north Queensland. Med J Aust. 2000;172(1):19–21.
MacIntyre CR, Burgess M, Isaacs D, McIntyre PB, Menzies R, Hull B. Epidemiology of severe hepatitis A in Indigenous Australian children. J Paediatr Child Health. 2007;43(5):383–7.
Thompson C, Dey A, Fearnley E, Polkinghorne B, Beard F. Impact of the national targeted Hepatitis A immunisation program in Australia: 2000–2014. Vaccine. 2017;35(1):170–6.
Jayasundara D, Hui BB, Regan DG, Heywood AE, MacIntyre CR, Wood JG. Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia. Vaccine. 2017;35(39):5228–34.
Heywood AE, Zwar N, Forssman BL, Seale H, Stephens N, Musto J et al. The contribution of travellers visiting friends and relatives to notified infectious diseases in Australia: state-based enhanced surveillance. Epidemiol Infect. 2016;144(16):3554–63.
Australian Government Department of Health. Hepatitis A case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 2013. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepa.htm.
Victoria State Government Department of Health and Human Services (DHHS). Hepatitis A outbreak - Update December 2018. [Internet.] Melbourne: Victoria State Government, DHHS; 20 December 2018. [Accessed on 26 June 2020.] Available from: https://www2.health.vic.gov.au/about/news-and-events/healthalerts/hepatitis-a-outbreak-december-2018.
NSW Health. Hepatitis A control guideline. [Internet.] Sydney: Government of New South Wales, NSW Health; 1 August 2019. [Accessed on 26 June 2020.] Available from: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/hepa.aspx.
NCIRS. Significant events in hepatitis A vaccination practice in Australia. Sydney: NCIRS; 2018. [Accessed on 26 June 2020.] Available from: http://www.ncirs.org.au/sites/default/files/2018-12/Hepatitis-A-history-Dec-2018.pdf.
Burrell S, Vodstrcil LA, Fairley CK, Kilner A, Bradshaw CS, Chen MY et al. Hepatitis A vaccine uptake among men who have sex with men from a time-limited vaccination programme in Melbourne in 2018. Sex Transm Infect. 2020;96(2):110–4.
Franklin N, Camphor H, Wright R, Stafford R, Glasgow K, Sheppeard V. Outbreak of hepatitis A genotype IB in Australia associated with imported frozen pomegranate arils. Epidemiol Infect. 2019;147. doi: https://doi.org/10.1017/S0950268818003515.
NSW Health. Hepatitis A linked to imported frozen pomegranate. [Internet.] Sydney: Government of New South Wales, NSW Health; 8 June 2018. [Accessed on 26 June 2020.] Available from: https://www.health.nsw.gov.au/Infectious/alerts/Pages/hep-A-pomegranate.aspx.
DHHS. Hepatitis A outbreak. [Internet.] Melbourne: Victoria State Government, DHHS; 20 September 2017. [Accessed on 26 June 2020.] Available from: https://www2.health.vic.gov.au/about/news-and-events/healthalerts/hepatitis-a-outbreak-september-2017.
WHO. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017;92(27):369–92.
Van Damme P, Ward JW, Shouval D, Zanetti A. 25 – Hepatitis B vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;342–74.e17. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000250.
Hepatitis, viral. II. Viral hepatitis B. In Heymann DL, ed. Control of Communicable Diseases Manual (19th edition). Washington, DC: APHA, 2008;284–93.
Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review. Med J Aust. 1996;165(6):322–6.
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228.
Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73.
O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health. 2004;28(3):212–6.
Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: chronic viral hepatitis. BMJ. 2001;322(7280):219–21.
Seed CR, Kiely P. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening. Vox Sang. 2013;105(4):290–8.
Australian Government Department of Health. Hepatitis B (newly acquired) case definition. Canberra: Australian Government Department of Health, CDNA; 1 July 2015. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbnew.htm.
McGregor S, King J, McManus H, Gray R, Guy R. 3.1 Hepatitis B notifications. In HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: University of New South Wales, Kirby Institute; 2018. [Accessed on 23 May 2021.] Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf#page=112.
Bresee JS, Fry AM, Sambhara S, Cox NJ. 31 – Inactivated influenza vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;456–88.e21. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000316.
Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362(9397):1733–45.
Li-Kim-Moy J, Yin JK, Patel C, Beard FH, Chiu C, Macartney KK et al. Australian vaccine preventable disease epidemiological review series: influenza 2006 to 2015. Commun Dis Intell Q Rep. 2016;40(4):E482–95.
Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine. 2017;35(4):521–8.
Mertz D, Lo CK, Lytvyn L, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis. BMC Infect Dis. 2019;19(1). doi: https://doi.org/10.1186/s12879-019-4318-3.
Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Mahdi SA et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30.
Australian Government Department of Health. Influenza laboratory-confirmed. [Internet.] Canberra: Australian Government Department of Health, CDNA; 29 October 2008. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_flu.htm.
ABS. Measuring excess mortality in Australia during the COVID-19 pandemic: Influenza and pneumonia (J09-J18). [Internet.] Canberra: ABS; 25 November 2020. [Accessed on 23 May 2021.] Available from: https://www.abs.gov.au/articles/measuring-excess-mortality-australia-during-covid-19-pandemic#influenza-and-pneumonia-j09-j18-.
Australian Government Department of Health. 2017 Influenza Season in Australia: A summary from the National Influenza Surveillance Committee. Canberra: Australian Government Department of Health; 22 November 2017. [Accessed on 26 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/097F15A91C05FBE7CA2581E20017F09E/$File/2017-season-summary-22112017.pdf.
Grant KA, Carville KS, Sullivan SG, Strachan J, Druce J, Fielding JE. A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia. Western Pac Surveill Response J. 2018;9(5 Suppl 1):18–26.
Sheridan SL, Patel C, Macartney K, Cheng AC. New enhanced influenza vaccines for older Australians: what promise do they hold? Med J Aust. 2018;209(3):110–2.
Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16(5):e321–31.
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–53.
Kwok KO, Riley S, Perera RAPM, Wei VWI, Wu P, Wei L et al. Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1. BMC Infect Dis. 2017;17(1). doi: https://doi.org/10.1186/s12879-017-2432-7.
Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–62.
Jester BJ, Uyeki TM, Jernigan DB. Fifty years of influenza A(H3N2) following the pandemic of 1968. Am J Public Health. 2020;110(5):669–76.
Blyth CC, Macartney KK, McRae J, Clark JE, Marshall HS, Buttery J et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2017: results from the PAEDS-FluCAN collaboration. Clin Infect Dis. 2019;68(6):940–8.
Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB et al. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.39.
Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill. 2017;22(43). doi: https://doi.org10.2807/1560-7917.ES.2017.22.43.17-00707.
Australian Government Department of Health. 2018 Influenza Season in Australia: A summary from the National Influenza Surveillance Committee. Canberra: Australian Government Department of Health; 16 November 2018. [Accessed on 26 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/CA086525758664B4CA25836200807AF9/$File/2018-Season-Summary.pdf.
Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB et al. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell (2018). 2019;43. doi: https://10.33321/cdi.2019.43.48.
Blyth CC, Cheng AC, Crawford NW, Clark JE, Buttery JP, Marshall HS et al. The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018. Vaccine. 2020;38(13):2779–87.
Kaczmarek MC, Ware RS, Lambert SB. The contribution of PCR testing to influenza and pertussis notifications in Australia. Epidemiol Infect. 2016;144(2):306–14.
Moss WJ. Measles. Lancet. 2017;390(10111):2490–502.
CDC. Measles. In Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and prevention of vaccine-preventable diseases. (13th edition.) Washington DC: Public Health Foundation; 2015.
Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004;189(Suppl 1):S4–16.
Strebel PM, Papania MJ, Gastañaduy PA, Goodson JL. 37 – Measles vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;579–618.e21. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000377.
Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007;36(6):1134–48.
Coughlin MM, Beck AS, Bankamp B, Rota PA. Perspective on global measles epidemiology and control and the role of novel vaccination strategies. Viruses. 2017;9(1). doi: https://doi.org/10.3390/v9010011.
MacIntyre CR, Kpozehouen E, Kunasekaran M, Harriman K, Conaty S, Rosewell A et al. Measles control in Australia - threats, opportunities and future needs. Vaccine. 2018;36(30):4393–8.
Funk S, Knapp JK, Lebo E, Reef SE, Dabbagh AJ, Kretsinger K et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019;17(1). doi: https://doi.org/10.1186/s12916-019-1413-7.
Patel MK, Dumolard L, Nedelec Y, Sodha SV, Steulet C, Gacic-Dobo M et al. Progress toward regional measles elimination - worldwide, 2000–2018. MMWR Morb Mortal Wkly Rep. 2019;68(48):1105–11.
Australian Government Department of Health. Measles – Elimination Achieved in Australia. [Internet.] Canberra: Australian Government Department of Health; 20 March 2014. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-measles-elim-announce-2014.htm.
Australian Government Department of Health. Measles case definition. Australian Government Department of Health, CDNA; 2004. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_measl.htm.
MacIntyre CR, Karki S, Sheikh M, Zwar N, Heywood AE. The role of travel in measles outbreaks in Australia – an enhanced surveillance study. Vaccine. 2016;34(37):4386–91.
Government of Western Australia Department of Health. Measles alert for Perth residents and overseas travellers. [Internet.] Perth: Government of Western Australia Department of Heath; 17 August 2018. [Accessed on 29 June 2020.] Available from: https://ww2.health.wa.gov.au/Media-releases/2018/Measles-alert-for-Perth-residents-and-overseas-travellers.
Heywood AE, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly HA. Elimination of endemic measles transmission in Australia. Bull World Health Organ. 2009;87(1):64–71.
Gibney KB, Attwood LO, Nicholson S, Tran T, Druce J, Healy J et al. Emergence of attenuated measles illness among IgG-positive/IgM-negative measles cases: Victoria, Australia, 2008–2017. Clin Infect Dis. 2020;70(6):1060–7.
Gidding HF, Quinn HE, Hueston L, Dwyer DE, McIntyre PB. Declining measles antibodies in the era of elimination: Australia’s experience. Vaccine. 2018;36(4):507–13.
NCIRS. Significant events in measles, mumps and rubella vaccination practice in Australia. Sydney: NCIRS; 2019. [Accessed on 29 June 2020.] Available from: http://ncirs.org.au/sites/default/files/2019-12/Measles-mumps-rubella-history-Dec%202019.pdf.
Granoff DM, Pollard AJ, Harrison LH. 39 – Meningococcal capsular group B vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;644–62.e6. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000535.
Harrison LH, Granoff DM, Pollard AJ. 38 – Meningococcal capsular group A, C, W, and Y conjugate vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;619–43.e11. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000389.
Apicella MA. Neisseria meningitidis. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (7th edition). Philadelphia: Churchill Livingstone Elsevier, 2010;2737–52.
Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. In Plotkin SA, Orenstein WA, Offit PA, eds. Plotkin’s Vaccines (6th edition). Philadelphia: Elsevier Saunders, 2013;388–418.
Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502–9.
Strifler L, Morris SK, Dang V, Tu HAT, Mindas RS, Jamieson FB et al. The health burden of invasive meningococcal disease: a systematic review. J Pediatric Infect Dis Soc. 2016;5(4):417–30.
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83.
Wang B, Clarke M, Thomas N, Howell S, Afzali HHA, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J. 2014;33(3):316–8.
Gibson A, Jorm L, McIntyre P. Using linked birth, notification, hospital and mortality data to examine false-positive meningococcal disease reporting and adjust disease incidence estimates for children in New South Wales, Australia. Epidemiol Infect. 2015;143(12):2570–9.
Australian Government Department of Health. Meningococcal disease (invasive) surveillance case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 19 January 2010. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_mening.htm.
Sudbury EL, O’Sullivan S, Lister D, Varghese D, Satharasinghe K. Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017. Emerg Infect Dis. 2020;26(7):1355–63.
Lahra MM, Enriquez R. Australian Meningococcal Surveillance Programme annual report, 2016. Commun Dis Intell Q Rep. 2017;41(4):E369–82.
Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2016;40(4):E503–11.
Lahra MM, Enriquez RP, George CRR. Australian Meningococcal Surveillance Programme annual report, 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.66.
Lahra MM, Enriquez RP, Hogan TP. Australian Meningococcal Surveillance Programme annual report, 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.10.
Martin NV, Ong KS, Howden BP, Lahra MM, Lambert SB, Beard FH et al. Rise in invasive serogroup W meningococcal disease in Australia 2013-2015. Commun Dis Intell Q Rep. 2016;40:E454–9.
Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470–80.
Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–28.
Campbell H, Ladhani S. The importance of surveillance: group W meningococcal disease outbreak response and control in England. Int Health. 2016;8(6):369–71.
Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015–2018. Clin Infect Dis. 2020;70(10):2036–44.
Northern Territory Government Department of Health. Health Alert: Meningococcal outbreak in Central Australia. [Internet.] Darwin: Northern Territory Government Department of Health; 26 September 2017. [Accessed on 29 June 2020.] Available from: http://mediareleases.nt.gov.au/mediaRelease/23733.
Northern Territory Government Department of Health. Update - Meningococcal outbreak in Central Australia. [Internet.] Darwin: Northern Territory Government Department of Health; 10 October 2017. [Accessed on 29 June 2020.] Available from: http://mediareleases.nt.gov.au/mediaRelease/23779.
Government of Western Australia Department of Health. Remote WA free meningococcal vaccine. [Internet.] Perth: Government of Western Australia Department of Health. Available from: https://ww2.health.wa.gov.au/Articles/N_R/Remote-WA-free-meningococcal-vaccine.
Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM et al. Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination. Med J Aust. 2017;207(9):382–7.
Patel C, Chiu CK, Beard FH, Crawford NW, Macartney K. One disease, two vaccines: challenges in prevention of meningococcal disease. Med J Aust. 2020;212(10). doi: https://doi.org/10.5694/mja2.50567.
Australian Government Department of Health. Quad-strain meningococcal vaccine to be added to National Immunisation Program. [Internet.] Canberra: Australian Government Department of Health, The Hon Greg Hunt MP; 2 February 2018. [Accessed on 29 June 2020.] Available from: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/quad-strain-meningococcal-vaccine-to-be-added-to-national-immunisation-program.
Australian Government Department of Health. $52 million to deliver free meningococcal vaccine to teenagers. [Internet.] Canberra: Australian Government Department of Health, The Hon Greg Hunt MP; 25 September 2018. [Accessed on 29 June 2020.] Available from: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/52-million-to-deliver-free-meningococcal-vaccine-to-teenagers.
Sharma K, Chiu C, Wood N. Meningococcal vaccines in Australia: a 2019 update. Aust Prescr. 2019;42(4):131–5.
Marshall HS, Lally N, Flood L, Phillips P. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust. 2020;212(2):89–93.
NCIRS. Significant events in meningococcal vaccination practice in Australia. Sydney: NCIRS; 2020. [Accessed on 29 June 2020.] Available from: http://ncirs.org.au/sites/default/files/2020-03/Meningococcal-history-Mar%202020.pdf.
Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–44.
Rubin SA. 40 – Mumps vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;663–88.e11. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000390.
Westphal DW, Eastwood A, Levy A, Davies J, Huppatz C, Gilles M et al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Dis. 2019;19(2):177–84.
Donahue M, Schneider A, Ukegbu U, Shah M, Riley J, Weigel A et al. Notes from the field: complications of mumps during a university outbreak among students who had received 2 doses of measles-mumps-rubella vaccine — Iowa, July 2015-May 2016. MMWR Morb Mortal Wkly Rep. 2017;66(14):390–1.
Kutty PK, Lawler J, Rausch-Phung E, Ortega-Sanchez IR, Goodell S, Schulte C et al. Epidemiology and the economic assessment of a mumps outbreak in a highly vaccinated population, Orange County, New York, 2009–2010. Hum Vaccin Immunother. 2014;10(5):1373–81.
Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17. doi: https://doi.org/10.3201/eid1704.101461.
Marshall HS, Plotkin S. The changing epidemiology of mumps in a high vaccination era. Lancet Infect Dis. 2019;19(2):118–9.
Beleni AI, Borgmann S. Mumps in the vaccination age: global epidemiology and the situation in Germany. Int J Environ Res Public Health. 2018;15. doi: https://doi.org/10.3390/ijerph15081618.
Centers for Disease Control and Prevention (CDC). Mumps cases and outbreaks. [Internet.] Atlanta: United States Government Department of Health and Human Services, CDC; 2017. [Accessed on 30 June 2020.] Available from: https://www.cdc.gov/mumps/outbreaks.html.
Fields VS, Safi H, Waters C, Dillaha J, Capelle L, Riklon S et al. Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report. Lancet Infect Dis. 2019;19(2):185–92.
Shah M, Quinlisk P, Weigel A, et al. Mumps outbreak in a highly vaccinated university-affiliated setting before and after a measles-mumps-rubella vaccination campaign—Iowa, July 2015–May 2016. Clin Infect Dis. 2018;66(1):81–8.
Vygen S, Fischer A, Meurice L, Njoya IM, Gregoris M, Ndiaye B et al. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill. 2016;21(10). doi: https://doi.org/10.2807/1560-7917.ES.2016.21.10.30156.
Albertson JP, Clegg WJ, Reid HD, Arbise BS, Pryde J, Vaid A et al. Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine — Illinois, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65(29):731–4.
Deeks SL, Lim GH, Simpson MA, Gagné L, Gubbay J, Kristjanson E et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183(9):1014–20.
Indenbaum V, Hübschen JM, Stein-Zamir C, Mendelson E, Sofer D, Hindiyeh M et al. Ongoing mumps outbreak in Israel, January to August 2017. Euro Surveill. 2017;22(35). doi: https://doi.org/10.2807/1560-7917.ES.2017.22.35.30605.
Willocks LJ, Guerendiain D, Austin HI, Morrison KE, Cameron RL, Templeton KE et al. An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. Epidemiol Infect. 2017;145(15):3219–25.
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4(4):CD004407. doi: https://doi.org/10.1002/14651858.CD004407.pub4.
Australian Government Department of Health. Mumps case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 12 March 2004. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_mumps.htm.
Westphal D, Quinn HE, Effler P. Vaccine effectiveness during a large mumps outbreak in Western Australia. 15th National Immunisation Conference, 7–9 June 2016. Brisbane: Public Health Association of Australia; 2016.
Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect. 2013;141(3):651–66.
Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017;377(10):947–56.
Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67:33–8.
Patel C, Beard F, Hendry A, Quinn H, Dey A, Macartney K et al. Australian mumps serosurvey 2012-2013: any cause for concern? Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.67.
Pertussis and parapertussis. In Heymann DL, ed. Control of Communicable Diseases Manual (19th edition). Washington, DC: APHA, 2008;455–61.
CDC. Pertussis. In Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and prevention of vaccine-preventable diseases. (13th edition.) Washington DC: Public Health Foundation; 2015.
Edwards KM, Decker MD. 44 – Pertussis vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;711–61.e16. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000432.
CDC. Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2005;54(50):1283–6.
Australian Government Department of Health. Pertussis case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 16 January 2014. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pertus.htm.
Allen TJ, Georgousakis M, Macartney K. Childhood immunisation in Australia: 2015 update. MedicineToday. 2015;16(7):16–23.
NCIRS. Significant events in diphtheria, tetanus and pertussis vaccination practice in Australia. Sydney: NCIRS; 2018. [Accessed on 30 June 2020.] Available from: http://www.ncirs.org.au/sites/default/files/2018-11/Diphtheria-tetanus-pertussis-history-July-2018.pdf.
Mak DB, Regan AK, Vo DT, Effler PV. Antenatal influenza and pertussis vaccination in Western Australia: a cross-sectional survey of vaccine uptake and influencing factors. BMC Pregnancy Childbirth. 2018;18(1):416. doi: https://doi.org/10.1186/s12884-018-2051-3.
Mohammed H, Clarke M, Koehler A, Watson M, Marshall H. Factors associated with uptake of influenza and pertussis vaccines among pregnant women in South Australia. PLoS One. 2018;13(6):e0197867. https://doi.org/10.1371/journal.pone.0197867.
Rowe SL, Perrett KP, Morey R, Stephens N, Cowie BC, Nolan TM et al. Influenza and pertussis vaccination of women during pregnancy in Victoria, 2015–2017. Med J Aust. 2019;210(10):454–62.
Leong RNF, Wood JG, Liu B, McIntyre PB, Newall AT. High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. Vaccine. 2020;38(19):3553–9.
Kandeil W, Atanasov P, Avramioti D, Fu J, Demarteau N, Li X. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines. 2019;18(5):439–55.
Musher DM. Streptococcus pneumoniae. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (7th edition). Philadelphia: Churchill Livingstone Elsevier, 2010;2623–42.
Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin North Am. 2015;29(4):679–97.
van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89–100.
Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51.
Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V et al. Long-term impact of a “3 + 0” Schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002–2014. Clin Infect Dis. 2017;64(2):175–83.
Pennington K, Enhanced Invasive Pneumococcal Disease Surveillance Working Group for the Communicable Diseases Network Australia. Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2019. Canberra: Australian Government Department of Health; 2019. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/15C3D92378263DBDCA257C9700814898/$File/IPD-jul-sept-2019-Qrt.pdf.
Australian Government Department of Health. Pneumococcal disease (invasive) case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 12 March 2004. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pnuemo.htm.
Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74.
Blyth CC, Jayasinghe S, Andrews RM. A rationale for change: an increase in invasive pneumococcal disease in fully vaccinated children. Clin Infect Dis. 2020;70(4):680–3.
Jayasinghe S. Pneumococcal disease and vaccination recommendations: the state of play. Respiratory Medicine Today. 2019;4(2):16–22.
Frank O, De Oliveira Bernardo C, González-Chica DA, Macartney K, Menzies R, Stocks N. Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice. Hum Vaccin Immunother. 2020;16(4):965–71.
Meder KN, Jayasinghe S, Beard F, Dey A, Kirk M, Cook H et al. Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalizations in Indigenous and non-Indigenous Australians. Clin Infect Dis. 2020;70(12):2607–15.
World Health Organization. Polio vaccines: WHO position paper, March 2016—recommendations. Vaccine. 2017;35(9):1197–9.
Poliomyelitis, acute. In Heymann DL, ed. Control of Communicable Diseases Manual (19th edition). Washington, DC: APHA, 2008;484–91.
Chard AN, Datta SD, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF et al. Progress toward polio eradication - worldwide, January 2018–March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–9.
Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep. 2006;55(40):1093–7.
Australian Government Department of Health. Poliovirus infection case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 1 January 2015. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_polio.htm.
AIHW. Polio in Australia. Canberra: Australian Government, AIHW; 2018. [Accessed on 13 February 2021.] Available from: https://www.aihw.gov.au/getmedia/ea7684ff-753c-44db-9091-24654db8b6b1/aihw-phe-236_Polio.pdf.
Paterson BJ, Durrheim DN. Review of Australia’s polio surveillance. Commun Dis Intell Q Rep. 2013;37(2):E149–55.
Roberts JA, Hobday LK, Ibrahim A, Thorley BR. Australian National Enterovirus Reference Laboratory annual report, 2016. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.25.
Roberts JA, Hobday LK, Ibrahim A, Thorley BR. Australian National Enterovirus Reference Laboratory annual report, 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.26.
Roberts JA, Hobday LK, Ibrahim A, Thorley BR. Australian National Enterovirus Reference Laboratory annual report, 2017. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.32.
Butler M, Paterson BJ, Martin N, Hobday L, Thorley B, Durrheim DN. ‘Silent’ and ‘noisy’ areas: acute flaccid paralysis surveillance at subnational level, Australia, 2001–2015. Int Health. 2017;9(3):190–4.
Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518–53.
Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367(9511):679–88.
Wade AJ, Cheng AC, Athan E, Molloy JL, Harris OC, Stenos J et al. Q fever outbreak at a cosmetics supply factory. Clin Infect Dis. 2006;42(7):e50–2.
Eldin C, Mélenotte C, Mediannikov O, Ghigo E, Million M, Edouard S et al. From Q fever to Coxiella burnetii infection: a paradigm change. Clin Microbiol Rev. 2017;30(1):115–90.
Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook. (10th edition.) Canberra: Australian Government Department of Health, ATAGI; 2013.
Hatchette TF, Hayes M, Merry H, Schlech WF, Marrie TJ. The effect of C. burnetii infection on the quality of life of patients following an outbreak of Q fever. Epidemiol Infect. 2003;130(3):491–5.
Kersh GJ, Anderson AD. Q Fever. In Heymann DL, ed. Control of Communicable Diseases Manual (20th edition). Washington DC: APHA; 19 January 2016. Available from: https://ccdm.aphapublications.org/doi/abs/10.2105/CCDM.2745.119.
Coste Mazeau P, Hantz S, Eyraud JL, Donadel L, Lacorre A, Rogez S et al. Q fever and pregnancy: experience from the Limoges Regional University Hospital. Arch Gynecol Obstet. 2016;294(2):233–8.
Ghanem-Zoubi N, Paul M. Q fever during pregnancy: a narrative review. Clin Microbiol Infect. 2020;26(7):864–70.
Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia’s national Q fever vaccination program. Vaccine. 2009;27(14):2037–41.
Armstrong M, Francis J, Robson J, Graves S, Mills D, Ferguson J et al. Q fever vaccination of children in Australia: limited experience to date. J Paediatr Child Health. 2019;55(9):1099–102.
Australian New Zealand Clinical Trials Registry (ANZCTR). Trial registered on ANZCTR: Safety and immunogenicity of Q fever vaccine in children aged 10 to 15 years (ACTRN12617000375358). ANZCTR; 13 March 2017. [Accessed on 21 February 2021.] Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372443.
Australian Government Department of Health. Q fever case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 12 March2004. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_qfev.htm.
Gidding HF, Faddy HM, Durrheim DN, Graves SR, Nguyen C, Hutchinson P et al. Seroprevalence of Q fever among metropolitan and non-metropolitan blood donors in New South Wales and Queensland, 2014–2015. Med J Aust. 2019;210(7):309–15.
Gidding HF, Peng CQ, Graves S, Massey P D, Nguyen C, Stenos J et al. Q fever seroprevalence in Australia suggests one in twenty people have been exposed. Epidemiol Infect. 2020;148. doi: https://doi.org/10.1017/S0950268820000084.
Francis JR, Robson JM. Q fever: more common than we think, and what this means for prevention. Med J Aust. 2019;210(7):305–6.
Sloan-Gardner TS, Massey PD, Hutchinson P, Knope K, Fearnley E. Trends and risk factors for human Q fever in Australia, 1991–2014. Epidemiol Infect. 2017;145(4):787–95.
Rahaman MR, Milazzo A, Marshall H, Bi P. Spatial, temporal, and occupational risks of Q fever infection in South Australia, 2007–2017. J Infect Public Health. 2020;13(4):544–51.
World Health Organization. Rotavirus vaccines. WHO position paper – January 2013. Wkly Epidemiol Rec. 2013;88(5):49–64.
Clark HF, Offit PA, Parashar UD. Rotavirus vaccines. In Plotkin SA, Orenstein WA, Offit PA, eds. Plotkin’s Vaccines (6th edition). Philadelphia: Elsevier Saunders, 2013; 715–34.
Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12(2):304–6.
Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow A L, Carter-Campbell S et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med. 1996;335(14):1022–8.
Roczo-Farkas S, Kirkwood CD, Cowley D, Barnes GL, Bishop RF, Bogdanovic-Sakran N et al. The impact of rotavirus vaccines on genotype diversity: a comprehensive analysis of 2 decades of Australian surveillance data. J Infect Dis. 2018;218(4):546–54.
Roczo-Farkas S, Cowley D, Bines JE. Australian Rotavirus Surveillance Program: annual report, 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.28.
Roczo-Farkas S, Kirkwood CD, Bines JE. Australian Rotavirus Surveillance Program: annual report, 2016. Commun Dis Intell Q Rep. 2017;41(4):E455–71.
Roczo-Farkas S, Kirkwood CD, Bines JE. Australian Rotavirus Surveillance Program annual report, 2015. Commun Dis Intell Q Rep. 2016;40(4):E527–38.
Australian Government Department of Health. Rotavirus case definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 26 June 2018. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedef-rotavirus.htm.
Newall AT, MacIntyre R, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. J Paediatr Child Health. 2006;42(9):521–7.
Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust. 2012;197(8):453–7.
Maguire JE, Glasgow K, Glass K, Roczo-Farkas S, Bines JE, Sheppeard V et al. Rotavirus epidemiology and monovalent rotavirus vaccine effectiveness in Australia: 2010–2017. Pediatrics. 2019;144(4). doi: https://doi.org/10.1542/peds.2019-1024.
Best JM. Rubella. Semin Fetal Neonatal Med. 2007;12(3):182–92.
Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015;385(9984):2297–307.
Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;320(8302):781–4.
Reef SE, Plotkin SA. 53 – Rubella vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;970–1000.e18. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000523.
Miller E. Rubella in the United Kingdom. Epidemiol Infect. 1991;107(1):31–42.
Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. Risk Anal. 2016;36(7):1315–31.
Grant GB, Desai S, Dumolard L, Kretsinger K, Reef SE. Progress toward rubella and congenital rubella syndrome control and elimination — worldwide, 2000–2018. MMWR Morb Mortal Wkly Rep. 2019;68(39):855–9.
Patel MK, Antoni S, Danovaro-Holliday MC, Desai S, Gacic-Dobo M, Nedelec Y et al. The epidemiology of rubella, 2007–18: an ecological analysis of surveillance data. Lancet Glob Health. 2020;8(11):e1399–407.
Australian Government Department of Health. Rubella case definition. [Internet.] Australian Government Department of Health, CDNA; 29 May 2019. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_rubela.htm.
Australian Government Department of Health. Rubella (congenital) case definition. [Internet.] Australian Government Department of Health, CDNA; 1 January 2016. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_conrub.htm.
Deverell M, Phu A, Zurynski Y, Elliott E. Australian Paediatric Surveillance Unit annual report, 2016. Commun Dis Intell Q Rep. 2017;41(3):E288–93.
Nunez CA, Morris A, Teutsch SM, McGregor S, Brotherton J, Novakovic D et al. Australian Paediatric Surveillance Unit annual report 2018. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.53.
Teutsch S, Zurynski Y, Elliott E. Australian Paediatric Surveillance Unit annual report, 2017. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00006-4.
Dey A, Knox S, Wang H, Beard FH, McIntyre PB. Summary of national surveillance data on vaccine preventable diseases in Australia, 2008-2011. Commun Dis Intell Q Rep. 2016;40(Suppl):S1–70.
Edirisuriya C, Beard FH, Hendry AJ, Dey A, Gidding HF, Hueston L et al. Australian rubella serosurvey 2012–2013: on track for elimination? Vaccine. 2018;36(20):2794–8.
Song N, Gao Z, Wood JG, Hueston L, Gilbert GL, MacIntyre CR et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine. 2012;30(27):4073–8.
Queensland Health. Rubella: Queensland Health Guidelines for Public Health Units. [Internet.] Queensland Government, Queensland Health; June 2019. [Accessed on 30 June 2020.] Available from: https://www.health.qld.gov.au/cdcg/index/rubella.
WHO. Chapter 4: Antibody detection methods for laboratory diagnosis and molecular epidemiology of measles, rubella, and congenital rubella syndrome. In Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome. (3rd edition.) Geneva: WHO; 2018. Available from: https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-4.pdf.
Roper MH, Wassilak SGF, Scobie HM, Ridpath AD, Orenstein WA. 58 – Tetanus toxoid. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;1052–79.e18. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000584.
World Health Organization. Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec. 2017;92(6):53–76.
Yen LM, Thwaites CL. Tetanus. Lancet. 2019;393(10181):1657–68.
Australian Government Department of Health. Tetanus case definition. [Internet.] Australian Government Department of Health, CDNA; 1 February 2012. [Accessed on 30 June 2020.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_tetanus.htm.
Gidding HF, Backhouse JL, Burgess MA, Gilbert GL. Immunity to diphtheria and tetanus in Australia: a national serosurvey. Med J Aust. 2005;183(6):301–4.
Lu X, Quinn HE, Menzies RI, Hueston L, McIntyre PB. Tetanus immunity and epidemiology in Australia, 1993–2010. Infect Disord Drug Targets. 2020;20(3):330–40.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Suppl):S1–167.
Quinn HE, McIntyre PB. Tetanus in the elderly – an important preventable disease in Australia. Vaccine. 2007;25(7):1304–9.
Gershon AA, Marin M, Seward JF. 62 – Varicella vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;1145–80.e17. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000626.
Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis. 1995;172(3):706–12.
Chickenpox/herpes zoster. In Heymann DL, ed. Control of Communicable Diseases Manual (19th edition). Washington, DC: APHA, 2008;109–16.
Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343(8912):1548–51.
Levin MJ. 65 – Zoster vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;1268–81.e6. Available from: http://www.sciencedirect.com/science/article/pii/B9780323357616000651.
Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain. 1999;3(4):335–42.
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–6.
Dayan RR, Peleg R. Herpes zoster - typical and atypical presentations. Postgrad Med. 2017;129(6):567–71.
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6). doi: https://doi.org/10.1136/bmjopen-2014-004833.
Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24(9):1308–14.
MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10(4). doi: https://doi.org/10.1371/journal.pone.0125025.
Costantino V, Gidding HF, Wood JG. Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection. Vaccine. 2017;35(48 part B):6737–42.
Australian Government Department of Health. Varicella-zoster infection (chickenpox) definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 6 March 2018. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedef-chickenpox.htm.
Australian Government Department of Health. Varicella-zoster infection (shingles) definition. [Internet.] Canberra: Australian Government Department of Health, CDNA; 8 March 2018. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedef-shingles.htm.
Australian Government Department of Health. Varicella-zoster infection (not elsewhere classified) definition. Canberra: Australian Government Department of Health, CDNA; 6 March 2018. [Accessed on 30 June 2020.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedef-varicella-unspec.htm.
Australian Government Department of Health. Clinical update: Zostavax® free for 70 to 79 year olds from November 2016. [Internet.] Canberra: Australian Government Department of Health; 21 December 2017. [Accessed on 3 July 2020.] Available from: https://www.health.gov.au/news/clinical-update-zostavaxr-free-for-70-to-79-year-olds-from-november-2016.
Jayasinghe S, Sheridan S, Macartney K. Herpes zoster vaccination in Australia: what’s available and who benefits? Aust Prescr. 2020;43(1):2–6.
NCIRS. Evaluation of the National Shingles Vaccination Program Process and early impact evaluation. Final report: 1 March 2019. Sydney: NCIRS; 2019. [Accessed on 3 July 2020.] Available from: http://ncirs.org.au/sites/default/files/2019-04/Shingles%20Program%20Evaluation%20Report_1%20March%202019_Final%20for%20web.pdf.
Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program. Vaccine. 2020;38(20):3646–52.
Litt J, Booy R, Bourke D, Dwyer DE, Leeb A, McCloud P et al. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Hum Vaccin Immunother. 2020;16(12):3081–9.
Sheel M, Beard FH, Dey A, Macartney K, McIntyre PB. Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Med J Aust. 2017;207(9):395–6.
Quinn HE, Gidding HF, Marshall HS, Booy R, Elliott EJ, Richmond P et al. Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. J Infect. 2019;78(3):220–5.
Sheel M, Beard F, Quinn H, Dey A, Kirk M, Koehler A et al. Australian vaccine preventable disease epidemiological review series: varicella-zoster virus infections, 1998–2015. Commun Dis Intell Q Rep. 2018;42. pii: S2209-6051(18)00002-7.
Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92(8):593–604.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
